| Title |
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial
|
|---|---|
| Published in |
Clinical Cancer Research, November 2021
|
| DOI | 10.1158/1078-0432.ccr-21-2283 |
| Pubmed ID | |
| Authors |
Meredith M. Regan, Opeyemi A. Jegede, Charlene M. Mantia, Thomas Powles, Lillian Werner, Robert J. Motzer, Nizar M. Tannir, Chung-Han Lee, Yoshihiko Tomita, Martin H. Voss, Elizabeth R. Plimack, Toni K. Choueiri, Brian I. Rini, Hans J. Hammers, Bernard Escudier, Laurence Albiges, Stephen Huo, Viviana Del Tejo, Brian Stwalley, Michael B. Atkins, David F. McDermott |
X Demographics
The data shown below were collected from the profiles of 45 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 14 | 31% |
| Spain | 4 | 9% |
| Mexico | 2 | 4% |
| Brazil | 2 | 4% |
| Philippines | 1 | 2% |
| United Kingdom | 1 | 2% |
| France | 1 | 2% |
| Argentina | 1 | 2% |
| Netherlands | 1 | 2% |
| Other | 3 | 7% |
| Unknown | 15 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 21 | 47% |
| Scientists | 12 | 27% |
| Practitioners (doctors, other healthcare professionals) | 11 | 24% |
| Science communicators (journalists, bloggers, editors) | 1 | 2% |
Mendeley readers
The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 29 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 3 | 10% |
| Student > Ph. D. Student | 3 | 10% |
| Researcher | 3 | 10% |
| Student > Postgraduate | 2 | 7% |
| Student > Bachelor | 1 | 3% |
| Other | 2 | 7% |
| Unknown | 15 | 52% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 6 | 21% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 7% |
| Chemical Engineering | 1 | 3% |
| Unspecified | 1 | 3% |
| Biochemistry, Genetics and Molecular Biology | 1 | 3% |
| Other | 3 | 10% |
| Unknown | 15 | 52% |
Attention Score in Context
This research output has an Altmetric Attention Score of 116. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 January 2022.
All research outputs
#348,676
of 24,792,566 outputs
Outputs from Clinical Cancer Research
#166
of 13,103 outputs
Outputs of similar age
#8,754
of 431,248 outputs
Outputs of similar age from Clinical Cancer Research
#4
of 108 outputs
Altmetric has tracked 24,792,566 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,103 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.5. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 431,248 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 108 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.